- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas.
McElnea cited a study Shields Health collaborated on with UMass Memorial where patients using their specialty pharmacy had $1,200 lower medical expenses than those elsewhere.
He shared how this helped the health system under value-based care, and said, "(that example) was a specific instance of the health system specialty pharmacy that had helped to position the whole health system to do better under a specific value-based care arrangement."
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
GLP-1s Are Flipping the Script, Says Doug Long | 2024 Asembia
May 1st 2024The growth in spending on the glucagon-like peptide 1 (GLP-1) agonists is a “mega tsunami,” said Doug Long, MBA, vice president industry relations for IQVIA. The script that specialty drugs are the main drivers of U.S. drug expenditures may need some revision.
Read More
